STAT Plus: Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead
Yesterday, I found out that I’m an “essential person” under Massachusetts’ new stay-at-home order. Should I update my LinkedIn? Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: Past due for a coronavirus antibody test; the opportunity for convalescent plasma; shameless fund-raising stunts; a biotech buyside investor survey; and more dogs of biotech.
STAT reader Erik R. emails: “Have you heard anything concerning ADMA Biologics and their participation in convalescent plasma or IVIG for treatment of Covid-19?”
Continue to STAT Plus to read the full story…
